Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The FDA has approved the first in class α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist for the treatment of seizures. Perampanel is an orally active noncompetitive AMPA antagonist. The drug is marketed by Eisai Inc. as Fycompa.

Pharmacology Update: Perampanel Tablets (Fycompa™)